QC
RGC icon

Quadrature Capital’s Regencell Bioscience RGC Stock Holding History

Quadrature Capital’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Buy
+41,750
New +$1M ﹤0.01% 1269

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $45.6B AUM 44.74% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $13.9B AUM 53.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Quadrature Capital's RGC Position: Q2 2026 in Review

Quadrature Capital opened a new position in Regencell Bioscience (RGC) in Q2 2026: 41,750 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #1269 among its holdings.

21 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Quadrature Capital held 41,750 shares of Regencell Bioscience worth $254K as of Q2 2026.
  • Regencell Bioscience was a new Quadrature Capital position in Q2 2026.
  • Regencell Bioscience made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1269 holding.
  • 21 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.